Etravirine vs Rilpivirine
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HIV
Shared mechanism: HIV reverse transcriptase · full HIV pipeline
Etravirine · Intelence
Marketed by Johnson & Johnson
NCT00254046 · Phase 3 · completed
Participants were randomized and blinded to etravirine or placebo on top of background therapy. A significantly larger share of patients on etravirine achieved viral suppression than on placebo.
Reported efficacy
Evaluation of efficacy, tolerability and safety of TMC125 as part of an antiretroviral therapy containing TMC114/ritonavir and an investigator selected optimized background regimen. (24 weeks): Confirmed viral load <50 copies/mL at week 24: TMC125 (etravirine) 56% (170/304) vs placebo 39% (119/308); difference in response rates 17% (95% CI 9-25), p=0.005 (met)
Result source: NCT00254046
Rilpivirine · Edurant
Marketed by Johnson & Johnson
NCT00540449 · Phase 3 · completed
This was a large (690-participant), randomized, quadruple-blinded, active-controlled (efavirenz) phase 3 trial with a hard clinical endpoint (confirmed viral load <50 copies/mL). The pre-specified non-inferiority margin was clearly met, with the confidence interval for the treatment difference falling entirely within the allowed -12% boundary, so rilpivirine was shown to be as effective as efavirenz on the primary measure despite a somewhat higher rate of virologic failure and resistance emergence as a secondary finding.
Next expected readout: December 2028 · NCT07637877 (registry estimate)
Reported efficacy
Number of Participants With Virological Response (Intent-to-Treat - Time to Loss of Virologic Response [TLOVR], <50 Copies/ml) at Week 48: Week 48 TLOVR virologic response: 287/346 rilpivirine vs 285/344 efavirenz; adjusted difference -0.4% (95% CI -5.9% to 5.2%), p<0.0001; non-inferiority margin -12%. (met)
Result source: NCT00540449
Results for HIV
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Etravirine | Rilpivirine |
|---|---|---|
| HIV-1 RNA below 50 copies/mL (week 48) | 56% vs 39%a+17 vs placeboNCT00254046 | 94% vs 94%vs CARNCT0242279712 other results
|
| HIV-1 RNA 50 copies/mL or more (week 48) | —Not posted · NCT00255099 | 0.6% vs 1%vs FTC/RPV/TDFNCT023452523 other results
|
| CD4 count, change (week 48) | —Not posted · NCT00255099 | 28 vs 18.4vs CARNCT0242279714 other results
|
HIV-1 RNA below 50 copies/mL (week 48)
- Etravirine
- 56% vs 39%a+17 vs placeboNCT00254046
- Rilpivirine
- 94% vs 94%vs CARNCT02422797
12 other results
- 93.7% vs 89.9% NCT01252940
- 95% vs 96% NCT02429791
- 93.7% vs 93.9% NCT02345252
- 90% vs 92% NCT02345226
- 85.8% vs 81.6% NCT01309243
- 97% vs 98% NCT02422797
- 98% vs 96% NCT02429791
- 93.9% vs 96.2% NCT01709084
- 89.3% vs 92.1% NCT01252940
- 89.2% vs 88.5% NCT02345252
- 85.2% vs 85.1% NCT02345226
- 77.9% vs 72.4% NCT01309243
HIV-1 RNA 50 copies/mL or more (week 48)
- Etravirine
- —Not posted · NCT00255099
- Rilpivirine
- 0.6% vs 1%vs FTC/RPV/TDFNCT02345252
3 other results
- 0.7% vs 0.9% NCT02345226
- 0.6% vs 0% NCT02345252
- 1.1% vs 0.9% NCT02345226
CD4 count, change (week 48)
- Etravirine
- —Not posted · NCT00255099
- Rilpivirine
- 28 vs 18.4vs CARNCT02422797
14 other results
- 42 vs 42.4 NCT02422797
- 12 vs 16 NCT02345252
- 12 vs 6 NCT02345226
- 278 vs 259 NCT01309243
- 32.3 vs 41.8 NCT02429791
- 9 vs -1 NCT02345252
- 23 vs 12 NCT02345226
- 10 vs -7 NCT01252940
- 200 vs 191 NCT01309243
- 16.2 vs 47.4 NCT02429791
- 20 vs 32 NCT01252940
- 145.9 vs 159.8 NCT00110305
- 158.9 vs 159.8 NCT00110305
- 172 vs 159.8 NCT00110305
- a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
3 other shared endpoints and safety
Coverage. Etravirine: 7 of 7 rows · Rilpivirine: 7 of 7 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Etravirine Rows use multiple source trials | Rilpivirine Rows use multiple source trials |
|---|---|---|
| CD4+ absolute change · cells/uL No placebo or comparator arm | 149.5 cells/uL @ 192wka,b,c NCT00128830 · Phase 2 · registry result, not featured evidence | 148.76 cells/uL @ 192wkd,a,b,c NCT01266902 · Phase 3 · registry result, not featured evidence show 3 more doses133.56 cells/uL @ 192wk NCT01266902 · Phase 3 · registry result, not featured evidence 132.73 cells/uL @ 192wk NCT01266902 · Phase 3 · registry result, not featured evidence 91.69 cells/uL @ 192wk NCT01266902 · Phase 3 · registry result, not featured evidence |
| HIV-1 RNA Less Than 50 Copies responder rate · % of participants No placebo or comparator arm | 45.5% (n=22) @ 48wk400/100 mgd,a,b,e NCT00896051 · Phase 2 · registry result, not featured evidence · combination show 1 more dose50% (n=22) @ 48wk300/100 mg NCT00896051 · Phase 2 · registry result, not featured evidence · combination | 85% (n=252) @ 148wka,b,e NCT02429791 · Phase 3 · registry result, not featured evidence · combination 1 other source trial84% (n=261) @ 148wkDTG 50 mg + RPV 25 mg NCT02422797 · Phase 3 · registry result, not featured evidence · combination |
| Virologic Response Rate Lt50 Copies responder rate · % of participants Maintenance | 62% vs 44% placebo @ 24wkf,b,c,g NCT00255099 · Phase 3 · sponsor-reported, not registry data | 76% (n=346) vs 78.8% (n=344) Efavirenz @ 96wk*f,b,c,g Responder NCT00540449 · Phase 3 · monotherapy · HIV · phase 3 · converted to % from 263 Participants as posted |
| Dropout rate | n/a: no completion milestoneh NCT00980538 · Phase 3 · registry result, not featured evidence show 13 more results20.3%400 mg once daily NCT00959894 · Phase 2 · registry result, not featured evidence 36%400/100 mg NCT00896051 · Phase 2 · registry result, not featured evidence · combination 40%300/100 mg NCT00896051 · Phase 2 · registry result, not featured evidence · combination 24.8% NCT00665847 · Phase 2 · registry result, not featured evidence 20.3% NCT00903682 · Phase 2 · registry result, not featured evidence 34.1% NCT00128830 · Phase 2 · registry result, not featured evidence 5%Cohort I: Treatment Experienced, 2 NCT01504841 · Phase 1/2 · registry result, not featured evidence 16.7%Cohort II: Treatment Experienced, NCT01504841 · Phase 1/2 · registry result, not featured evidence —200 mg + 200 mg NCT04630002 · Phase 1 · registry result, not featured evidence · combination —200 mg + 600/100 mg + 200 mg NCT04630002 · Phase 1 · registry result, not featured evidence · combination 17.9% NCT00871234 · Phase 1 · registry result, not featured evidence 0% NCT01625169 · Phase na · registry result, not featured evidence · combination — NCT01427504 · Phase na · registry result, not featured evidence · combination | 24.3%i NCT00540449 · Phase 3 · monotherapy · HIV · phase 3 show 32 more results20% NCT00543725 · Phase 3 · monotherapy · HIV · phase 3 5.2%DTG + RPV NCT02429791 · Phase 3 · registry result, not featured evidence · combination —DTG + RPV (Continuation Phase) NCT02429791 · Phase 3 · registry result, not featured evidence · combination —DTG + RPV (Early + Late Switch) NCT02429791 · Phase 3 · registry result, not featured evidence · combination —DTG + RPV (Early Switch) NCT02429791 · Phase 3 · registry result, not featured evidence · combination 6.1%DTG 50 mg + RPV 25 mg NCT02422797 · Phase 3 · registry result, not featured evidence · combination —DTG 50 mg + RPV 25 mg NCT02422797 · Phase 3 · registry result, not featured evidence · combination —DTG 50 mg + RPV 25 mg NCT02422797 · Phase 3 · registry result, not featured evidence · combination —DTG 50 mg + RPV 25 mg NCT02422797 · Phase 3 · registry result, not featured evidence · combination 7.5% NCT01709084 · Phase 3 · registry result, not featured evidence 22.3%RPV (TMC278-TiDP6-C209 [C209] and NCT01266902 · Phase 3 · registry result, not featured evidence 25.2%Rilpivirine (RPV) (TMC278-C204 [C2 NCT01266902 · Phase 3 · registry result, not featured evidence 12.7%FTC/RPV/TAF NCT02345252 · Phase 3 · registry result, not featured evidence —FTC/RPV/TAF (Double-Blind Phase) NCT02345252 · Phase 3 · registry result, not featured evidence —Open-Label FTC/RPV/TAF From FTC/RP NCT02345252 · Phase 3 · registry result, not featured evidence —Open-Label FTC/RPV/TAF From FTC/RP NCT02345252 · Phase 3 · registry result, not featured evidence 15.7%FTC/RPV/TAF NCT02345226 · Phase 3 · registry result, not featured evidence —FTC/RPV/TAF (Double-Blind Phase) NCT02345226 · Phase 3 · registry result, not featured evidence —Open-Label FTC/RPV/TAF From EFV/FT NCT02345226 · Phase 3 · registry result, not featured evidence —Open-Label FTC/RPV/TAF From FTC/RP NCT02345226 · Phase 3 · registry result, not featured evidence 8.1% NCT01252940 · Phase 3 · registry result, not featured evidence 21% NCT01309243 · Phase 3 · registry result, not featured evidence 0% NCT04012931 · Phase 2 · registry result, not featured evidence 30.6%25 mg NCT00799864 · Phase 2 · registry result, not featured evidence 40%25 mg NCT00799864 · Phase 2 · registry result, not featured evidence 33.3%25 mg NCT00799864 · Phase 2 · registry result, not featured evidence 0%15 mg NCT00799864 · Phase 2 · registry result, not featured evidence 0%12.5 mg NCT00799864 · Phase 2 · registry result, not featured evidence 12.1% NCT02165202 · Phase 2 · registry result, not featured evidence 4% NCT01286740 · Phase 2 · registry result, not featured evidence 0%50mg/25mg NCT03984838 · Phase 1 · registry result, not featured evidence 7.1% NCT01562886 · Phase 1 · registry result, not featured evidence · combination |
| Discontinued due to AEs | 6.7%h NCT00980538 · Phase 3 · registry result, not featured evidence show 13 more results3.8%400 mg once daily NCT00959894 · Phase 2 · registry result, not featured evidence 4%400/100 mg NCT00896051 · Phase 2 · registry result, not featured evidence · combination 8%300/100 mg NCT00896051 · Phase 2 · registry result, not featured evidence · combination 7.9% NCT00665847 · Phase 2 · registry result, not featured evidence 7.6% NCT00903682 · Phase 2 · registry result, not featured evidence 4.7% NCT00128830 · Phase 2 · registry result, not featured evidence —Cohort I: Treatment Experienced, 2 NCT01504841 · Phase 1/2 · registry result, not featured evidence —Cohort II: Treatment Experienced, NCT01504841 · Phase 1/2 · registry result, not featured evidence —200 mg + 200 mg NCT04630002 · Phase 1 · registry result, not featured evidence · combination —200 mg + 600/100 mg + 200 mg NCT04630002 · Phase 1 · registry result, not featured evidence · combination 7.1% NCT00871234 · Phase 1 · registry result, not featured evidence — NCT01625169 · Phase na · registry result, not featured evidence · combination — NCT01427504 · Phase na · registry result, not featured evidence · combination | 3.5%i NCT00540449 · Phase 3 · monotherapy · HIV · phase 3 show 32 more results5.3% NCT00543725 · Phase 3 · monotherapy · HIV · phase 3 2.4%DTG + RPV NCT02429791 · Phase 3 · registry result, not featured evidence · combination —DTG + RPV (Continuation Phase) NCT02429791 · Phase 3 · registry result, not featured evidence · combination —DTG + RPV (Early + Late Switch) NCT02429791 · Phase 3 · registry result, not featured evidence · combination —DTG + RPV (Early Switch) NCT02429791 · Phase 3 · registry result, not featured evidence · combination 4.2%DTG 50 mg + RPV 25 mg NCT02422797 · Phase 3 · registry result, not featured evidence · combination —DTG 50 mg + RPV 25 mg NCT02422797 · Phase 3 · registry result, not featured evidence · combination —DTG 50 mg + RPV 25 mg NCT02422797 · Phase 3 · registry result, not featured evidence · combination —DTG 50 mg + RPV 25 mg NCT02422797 · Phase 3 · registry result, not featured evidence · combination 2.3% NCT01709084 · Phase 3 · registry result, not featured evidence 3%RPV (TMC278-TiDP6-C209 [C209] and NCT01266902 · Phase 3 · registry result, not featured evidence 2.5%Rilpivirine (RPV) (TMC278-C204 [C2 NCT01266902 · Phase 3 · registry result, not featured evidence 0.6%FTC/RPV/TAF NCT02345252 · Phase 3 · registry result, not featured evidence —FTC/RPV/TAF (Double-Blind Phase) NCT02345252 · Phase 3 · registry result, not featured evidence —Open-Label FTC/RPV/TAF From FTC/RP NCT02345252 · Phase 3 · registry result, not featured evidence —Open-Label FTC/RPV/TAF From FTC/RP NCT02345252 · Phase 3 · registry result, not featured evidence 1.1%FTC/RPV/TAF NCT02345226 · Phase 3 · registry result, not featured evidence —FTC/RPV/TAF (Double-Blind Phase) NCT02345226 · Phase 3 · registry result, not featured evidence —Open-Label FTC/RPV/TAF From EFV/FT NCT02345226 · Phase 3 · registry result, not featured evidence —Open-Label FTC/RPV/TAF From FTC/RP NCT02345226 · Phase 3 · registry result, not featured evidence 0.9% NCT01252940 · Phase 3 · registry result, not featured evidence 3% NCT01309243 · Phase 3 · registry result, not featured evidence — NCT04012931 · Phase 2 · registry result, not featured evidence —25 mg NCT00799864 · Phase 2 · registry result, not featured evidence —25 mg NCT00799864 · Phase 2 · registry result, not featured evidence —25 mg NCT00799864 · Phase 2 · registry result, not featured evidence —15 mg NCT00799864 · Phase 2 · registry result, not featured evidence —12.5 mg NCT00799864 · Phase 2 · registry result, not featured evidence — NCT02165202 · Phase 2 · registry result, not featured evidence — NCT01286740 · Phase 2 · registry result, not featured evidence —50mg/25mg NCT03984838 · Phase 1 · registry result, not featured evidence — NCT01562886 · Phase 1 · registry result, not featured evidence · combination |
| Serious AEs | 10%h NCT00980538 · Phase 3 · registry result, not featured evidence show 13 more results15.2%400 mg once daily NCT00959894 · Phase 2 · registry result, not featured evidence 8%400/100 mg NCT00896051 · Phase 2 · registry result, not featured evidence · combination 16%300/100 mg NCT00896051 · Phase 2 · registry result, not featured evidence · combination 5% NCT00665847 · Phase 2 · registry result, not featured evidence 13.9% NCT00903682 · Phase 2 · registry result, not featured evidence 21.8% NCT00128830 · Phase 2 · registry result, not featured evidence 25%Cohort I: Treatment Experienced, 2 NCT01504841 · Phase 1/2 · registry result, not featured evidence 50%Cohort II: Treatment Experienced, NCT01504841 · Phase 1/2 · registry result, not featured evidence 0%200 mg + 200 mg NCT04630002 · Phase 1 · registry result, not featured evidence · combination 0%200 mg + 600/100 mg + 200 mg NCT04630002 · Phase 1 · registry result, not featured evidence · combination 0% NCT00871234 · Phase 1 · registry result, not featured evidence 0% NCT01625169 · Phase na · registry result, not featured evidence · combination 20% NCT01427504 · Phase na · registry result, not featured evidence · combination | 11.6%i NCT00540449 · Phase 3 · monotherapy · HIV · phase 3 show 32 more results9.4% NCT00543725 · Phase 3 · monotherapy · HIV · phase 3 —DTG + RPV NCT02429791 · Phase 3 · registry result, not featured evidence · combination 3.2%DTG + RPV (Continuation Phase) NCT02429791 · Phase 3 · registry result, not featured evidence · combination 13.5%DTG + RPV (Early + Late Switch) NCT02429791 · Phase 3 · registry result, not featured evidence · combination 4%DTG + RPV (Early Switch) NCT02429791 · Phase 3 · registry result, not featured evidence · combination —DTG 50 mg + RPV 25 mg NCT02422797 · Phase 3 · registry result, not featured evidence · combination 5.8%DTG 50 mg + RPV 25 mg NCT02422797 · Phase 3 · registry result, not featured evidence · combination 14.6%DTG 50 mg + RPV 25 mg NCT02422797 · Phase 3 · registry result, not featured evidence · combination 7.3%DTG 50 mg + RPV 25 mg NCT02422797 · Phase 3 · registry result, not featured evidence · combination 7.5% NCT01709084 · Phase 3 · registry result, not featured evidence 4.4%RPV (TMC278-TiDP6-C209 [C209] and NCT01266902 · Phase 3 · registry result, not featured evidence 7.6%Rilpivirine (RPV) (TMC278-C204 [C2 NCT01266902 · Phase 3 · registry result, not featured evidence —FTC/RPV/TAF NCT02345252 · Phase 3 · registry result, not featured evidence 11.4%FTC/RPV/TAF (Double-Blind Phase) NCT02345252 · Phase 3 · registry result, not featured evidence 5.3%Open-Label FTC/RPV/TAF From FTC/RP NCT02345252 · Phase 3 · registry result, not featured evidence 0%Open-Label FTC/RPV/TAF From FTC/RP NCT02345252 · Phase 3 · registry result, not featured evidence —FTC/RPV/TAF NCT02345226 · Phase 3 · registry result, not featured evidence 12.3%FTC/RPV/TAF (Double-Blind Phase) NCT02345226 · Phase 3 · registry result, not featured evidence 4.8%Open-Label FTC/RPV/TAF From EFV/FT NCT02345226 · Phase 3 · registry result, not featured evidence 0%Open-Label FTC/RPV/TAF From FTC/RP NCT02345226 · Phase 3 · registry result, not featured evidence 6.6% NCT01252940 · Phase 3 · registry result, not featured evidence 9.1% NCT01309243 · Phase 3 · registry result, not featured evidence 0% NCT04012931 · Phase 2 · registry result, not featured evidence 16.7%25 mg NCT00799864 · Phase 2 · registry result, not featured evidence 0%25 mg NCT00799864 · Phase 2 · registry result, not featured evidence 0%25 mg NCT00799864 · Phase 2 · registry result, not featured evidence 0%15 mg NCT00799864 · Phase 2 · registry result, not featured evidence 0%12.5 mg NCT00799864 · Phase 2 · registry result, not featured evidence 4.4% NCT02165202 · Phase 2 · registry result, not featured evidence 2% NCT01286740 · Phase 2 · registry result, not featured evidence 0%50mg/25mg NCT03984838 · Phase 1 · registry result, not featured evidence 0% NCT01562886 · Phase 1 · registry result, not featured evidence · combination |
| Most frequent reported AEs | h cough 2.8% upper respiratory tract infection 2.8% pregnancy 2.2% NCT00980538 · Phase 3 · registry result, not featured evidence show 13 more results400 mg once daily elevated level of transaminase 11.4% hyperbilirubinemia 7.6% hyperlipidemia 7.6% NCT00959894 · Phase 2 · registry result, not featured evidence 400/100 mg cough 16% headache 12% influenza 12% NCT00896051 · Phase 2 · registry result, not featured evidence · combination 300/100 mg cough 20% nausea 16% blood bilirubin increased 12% NCT00896051 · Phase 2 · registry result, not featured evidence · combination upper respiratory tract infection 26.7% diarrhoea 15.8% cough 12.9% NCT00665847 · Phase 2 · registry result, not featured evidence nasopharyngitis 21.5% headache 16.5% diarrhoea 10.1% NCT00903682 · Phase 2 · registry result, not featured evidence diarrhoea 17.5% upper respiratory tract infection 17.1% sinusitis 11.4% NCT00128830 · Phase 2 · registry result, not featured evidence blood bicarbonate decreased 90% blood sodium decreased 70% nasal congestion 70% NCT01504841 · Phase 1/2 · registry result, not featured evidence cough 100% nasal congestion 100% rhinorrhoea 100% NCT01504841 · Phase 1/2 · registry result, not featured evidence 200 mg + 200 mg headache 18.8% toothache 12.5% diarrhoea 6.3% NCT04630002 · Phase 1 · registry result, not featured evidence · combination 200 mg + 600/100 mg + 200 mg rash maculo-papular 20% scleral hyperaemia 20% headache 13.3% NCT04630002 · Phase 1 · registry result, not featured evidence · combination headache 14.3% constipation 10.7% diarrhea 7.1% NCT00871234 · Phase 1 · registry result, not featured evidence breast tenderness 66.7% diarrhea 11.1% headache 11.1% NCT01625169 · Phase na · registry result, not featured evidence · combination altered taste 64% headache 16% rash 16% NCT01427504 · Phase na · registry result, not featured evidence · combination | i upper respiratory tract infection 15.3% diarrhoea 14.7% headache 14.5% NCT00540449 · Phase 3 · monotherapy · HIV · phase 3 show 28 more resultsarthralgia 0% back pain 0% bronchitis 0% NCT02429791 · Phase 3 · registry result, not featured evidence · combination nasopharyngitis 20.6% headache 14.7% diarrhoea 13.9% NCT02429791 · Phase 3 · registry result, not featured evidence · combination nasopharyngitis 10.7% headache 9.5% diarrhoea 8.7% NCT02429791 · Phase 3 · registry result, not featured evidence · combination DTG 50 mg + RPV 25 mg arthralgia 0% asthenia 0% back pain 0% NCT02422797 · Phase 3 · registry result, not featured evidence · combination DTG 50 mg + RPV 25 mg nasopharyngitis 18.4% upper respiratory tract infection 14.2% bronchitis 10.7% NCT02422797 · Phase 3 · registry result, not featured evidence · combination DTG 50 mg + RPV 25 mg nasopharyngitis 8% upper respiratory tract infection 7.3% arthralgia 6.5% NCT02422797 · Phase 3 · registry result, not featured evidence · combination upper respiratory tract infection 29.6% headache 17.8% urinary tract infection 13.6% NCT01709084 · Phase 3 · registry result, not featured evidence pregnancy 1.9% headache 1.1% alanine aminotransferase increased 0.8% NCT01266902 · Phase 3 · registry result, not featured evidence facial wasting 1.7% hepatitis c 1.7% hypertension 1.7% NCT01266902 · Phase 3 · registry result, not featured evidence nasopharyngitis 15.5% upper respiratory tract infection 14.9% diarrhoea 10.8% NCT02345252 · Phase 3 · registry result, not featured evidence back pain 10.5% conjunctivitis allergic 10.5% cough 10.5% NCT02345252 · Phase 3 · registry result, not featured evidence cough 17.6% nasopharyngitis 17.6% pyrexia 17.6% NCT02345252 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 16.9% nasopharyngitis 11.6% cough 10.3% NCT02345226 · Phase 3 · registry result, not featured evidence rhinitis 16% nasopharyngitis 12% bronchitis 8% NCT02345226 · Phase 3 · registry result, not featured evidence nasopharyngitis 11% diarrhoea 10.7% headache 9.8% NCT01252940 · Phase 3 · registry result, not featured evidence diarrhoea 17.5% nausea 16.5% upper respiratory tract infection 14.5% NCT01309243 · Phase 3 · registry result, not featured evidence vomiting 15.4% alanine aminotransferase increased 11.5% abdominal pain 7.7% NCT04012931 · Phase 2 · registry result, not featured evidence 25 mg upper respiratory tract infection 55.6% influenza 41.7% cough 27.8% NCT00799864 · Phase 2 · registry result, not featured evidence 25 mg upper respiratory tract infection 60% toothache 40% alanine aminotransferase increased 20% NCT00799864 · Phase 2 · registry result, not featured evidence 25 mg upper respiratory tract infection 55.6% decreased appetite 22.2% diarrhoea 22.2% NCT00799864 · Phase 2 · registry result, not featured evidence 15 mg upper respiratory tract infection 100% anaemia 50% dermatitis atopic 50% NCT00799864 · Phase 2 · registry result, not featured evidence 12.5 mg upper respiratory tract infection 100% cough 50% lower respiratory tract infection 50% NCT00799864 · Phase 2 · registry result, not featured evidence injection site pain 75% (placebo 40.5%) injection site pruritus 36.3% (placebo 11.9%) injection site swelling 36.3% (placebo 7.1%) NCT02165202 · Phase 2 · registry result, not featured evidence diarrhoea 16.3% upper respiratory tract infection 14.3% insomnia 12.2% NCT01286740 · Phase 2 · registry result, not featured evidence 50mg/25mg headache 6.3% vessel puncture site bruise 6.3% vomiting 6.3% NCT03984838 · Phase 1 · registry result, not featured evidence insomnia 23.1% NCT01562886 · Phase 1 · registry result, not featured evidence · combination |
Notes
- aTrial phases differ: Phase 3 versus Phase 2.
- bPopulation comparability has not been reviewed for both studies.
- cTreatment context has not been resolved for both arms.
- dThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- eAssessment timepoints differ: 148 weeks versus 48 weeks.
- fThe reported result categories differ.
- gAssessment timepoints differ: 96 weeks versus 24 weeks.
- hPopulation comparability has not been reviewed for these studies.
- iPopulation comparability has not been reviewed for 31 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Etravirine
show 2 more results
show 2 more results
show 7 more results
show 1 more result
show 7 more results
show 1 more result
show 1 more result
show 1 more result
show 5 more results
show 1 more result
+ 5 further endpoints in the CSV export.
Rilpivirine
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 14 more results
+ 18 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Etravirine's landscape · Rilpivirine's landscape